Innoviva, Inc. (INVA) Stock
INVA Key Statistics
About Innoviva, Inc.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
CEO: Pavel Raifeld. Company website
INVA — Frequently Asked Questions
What is the INVA stock price today?
Innoviva, Inc. (INVA) trades at $21.14, up 0.43% on the day, as of Sep 20, 2026 15:01 UTC.
What is Innoviva, Inc.'s market cap?
Innoviva, Inc. has a market capitalisation of $1.56B, calculated from the live INVA share price and shares outstanding.
What is the P/E ratio of INVA?
INVA trades at a trailing P/E of 5.16, from earnings per share of $4.10 over the last twelve months.
How much revenue does Innoviva, Inc. make?
Innoviva, Inc. generated revenue of $443.43M over the trailing twelve months, which puts the stock at 3.52 times sales.
What is the 52-week range for INVA?
INVA has traded between $16.52 and $25.15 over the past 52 weeks, and the last price is 15.9% below that high.
Is Innoviva, Inc. profitable?
Yes. Innoviva, Inc. keeps 80.56% of revenue as net income over the trailing twelve months.
What is the analyst price target for INVA?
Wall Street analysts rate INVA Buy, with an average price target of $38.00, 79.8% above the current price.
What sector is Innoviva, Inc. in?
Innoviva, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Innoviva, Inc.?
Pavel Raifeld is the chief executive of Innoviva, Inc., which employs 159 people.
Where can I track INVA in real time?
QFI Terminal shows INVA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See INVA live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open INVA in Terminal See plans